{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:30:17Z","timestamp":1720708217971},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.ackd.2010.11.003","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T09:05:35Z","timestamp":1294650335000},"page":"42-47","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacologic Issues in Treating Hypertension in CKD"],"prefix":"10.1053","volume":"18","author":[{"given":"Domenic A.","family":"Sica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2010.11.003_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semnephrol.2005.03.001","article-title":"Pathologic basis and treatment considerations in chronic kidney disease-related hypertension","volume":"25","author":"Sica","year":"2005","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2010.11.003_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1681\/ASN.2010030236","article-title":"Blood pressure control in chronic kidney disease: is less really more?","volume":"21","author":"Lewis","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.11.003_bib3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl\u00a01","key":"10.1053\/j.ackd.2010.11.003_bib4","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI)","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.11.003_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of\u00a0the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1527-5299.2003.01907.x","article-title":"Metolazone and its role in edema management","volume":"9","author":"Sica","year":"2003","journal-title":"Congest Heart Fail"},{"key":"10.1053\/j.ackd.2010.11.003_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0002-9343(82)90523-X","article-title":"Disorders of body fluids, sodium and potassium in chronic renal failure","volume":"72","author":"Mitch","year":"1982","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.11.003_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11897-005-0011-5","article-title":"The risks and benefits of aldosterone antagonists","volume":"2","author":"Sica","year":"2005","journal-title":"Curr Heart Fail Rep"},{"key":"10.1053\/j.ackd.2010.11.003_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety","volume":"39","author":"Santos","year":"2003","journal-title":"J Hepatol"},{"key":"10.1053\/j.ackd.2010.11.003_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","article-title":"Eplerenone: a new aldosterone receptor antagonist: are the\u00a0FDA\u2019s restrictions appropriate","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.ackd.2010.11.003_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/HYPERTENSIONAHA.108.128017","article-title":"Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not","volume":"53","author":"Sica","year":"2009","journal-title":"Hypertension"},{"issue":"suppl 10","key":"10.1053\/j.ackd.2010.11.003_bib17","first-page":"S13","article-title":"Kinetics of angiotensin converting enzyme inhibitors in renal failure","volume":"20","author":"Sica","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.ackd.2010.11.003_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/ajkd.2002.34883","article-title":"Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy","volume":"40","author":"Haas","year":"2002","journal-title":"Am J\u00a0Kidney Dis"},{"key":"10.1053\/j.ackd.2010.11.003_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11906-009-0058-x","article-title":"Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy","volume":"11","author":"Tobe","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"10.1053\/j.ackd.2010.11.003_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/01.CIR.0000047526.08376.80","article-title":"Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies","volume":"107","author":"Ruggenenti","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2010.11.003_bib21","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2010.11.003_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11906-003-0043-8","article-title":"Renal handling of angiotensin receptor blockers: clinical relevance","volume":"5","author":"Sica","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1053\/j.ackd.2010.11.003_bib23","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.11.003_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200746080-00003","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment","volume":"46","author":"Vaidyanathan","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ackd.2010.11.003_bib25","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2\u00a0diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00041552-200303000-00001","article-title":"Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations","volume":"12","author":"Sica","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2010.11.003_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ajh\/2.7.537","article-title":"Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide","volume":"2","author":"Chrysant","year":"1989","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2010.11.003_bib28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1524-6175.2001.00484.x","article-title":"Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension","volume":"3","author":"Sica","year":"2001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.ackd.2010.11.003_bib29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2010.11.003_bib30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.11.003_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00003088-200241070-00004","article-title":"Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines","volume":"41","author":"Frishman","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ackd.2010.11.003_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mhj.2002.125513","article-title":"Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease","volume":"144","author":"McCullough","year":"2002","journal-title":"Am Heart J"},{"issue":"9 Pt 2","key":"10.1053\/j.ackd.2010.11.003_bib33","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0895-7061(03)00968-3","article-title":"Role for beta-blockers in the management of diabetic kidney disease","volume":"16","author":"Bakris","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2010.11.003_bib34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1681\/ASN.2008040402","article-title":"Sympathetic activation in chronic renal failure","volume":"20","author":"Schlaich","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 2","key":"10.1053\/j.ackd.2010.11.003_bib35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1378\/chest.83.2_Supplement.386","article-title":"Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function","volume":"83","author":"Lowenthal","year":"1983","journal-title":"Chest"},{"key":"10.1053\/j.ackd.2010.11.003_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1524-6175.2005.04133.x","article-title":"Transdermal clonidine: therapeutic considerations","volume":"7","author":"Sica","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.ackd.2010.11.003_bib37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/039139880202501104","article-title":"Strategy for the treatment of noncompliant hypertensive hemodialysis patients","volume":"25","author":"Ross","year":"2002","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ackd.2010.11.003_bib38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archinte.148.3.729","article-title":"Risk factors for severe bradycardia during oral clonidine therapy for hypertension","volume":"148","author":"Byrd","year":"1988","journal-title":"Arch Intern Med"},{"issue":"5 Pt 1","key":"10.1053\/j.ackd.2010.11.003_bib39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0895-7061(99)00225-3","article-title":"The addition of doxazosin to the\u00a0therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study","volume":"13","author":"Black","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2010.11.003_bib40","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1464-5491.2005.01636.x","article-title":"Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy","volume":"22","author":"Yasuda","year":"2005","journal-title":"Diabet Med"},{"key":"10.1053\/j.ackd.2010.11.003_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1291\/hypres.24.359","article-title":"Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure","volume":"24","author":"Mori","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ackd.2010.11.003_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1468-6708-3-7","article-title":"A review of the adverse effects of peripheral alpha-1 antagonists in hypertension therapy","volume":"3","author":"Bryson","year":"2002","journal-title":"Curr Control Trials Cardiovasc Med"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510001783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510001783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T18:45:32Z","timestamp":1559933132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559510001783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1548559510001783"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2010.11.003","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}